Mall of America

Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6

Retrieved on: 
Monday, May 8, 2023
Volunteering, AMP, CSO, Pharmacokinetics, Gram-negative bacteria, Acinetobacter baumannii, Plasma, Patient, Blood, Mall of America, Phenotype, Safety, Peptide, Pharmaceutical industry, Vaccine

JERUSALEM, Israel, May 8th, 2023 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. All endpoints were met: No severe or serious adverse events (SEs/SAEs) were observed at any dose level in the study while clinically meaningful levels of OMN6 were achieved in the blood and complete clearance of the drug was demonstrated, allowing for multiple daily infusions as is common with anti-infective treatments.

Key Points: 
  • The secondary endpoint was to evaluate the pharmacokinetics (PK) of OMN6 in the plasma of healthy young and elderly adult volunteers.
  • As a result, Omnix Medical believes that its novel peptides can be considered a new class of antimicrobial drugs.
  • "We are very pleased with these results," said Dr. Moshik Cohen-Kutner, CEO of Omnix Medical.
  • We are now looking forward to preparing a Phase II trial with OMN6 in the coming months."

EQS-News: Abivax reports 2022 financial results and operations update

Retrieved on: 
Wednesday, April 19, 2023
Operating cost, CD, US Foods, Marketing, United European Gastroenterology, G&A, Malignancy, Congress, COVID-19, Investment, Patient, Ageing, ITT, ARD, HCC, Rheumatoid arthritis, Maintenance, Sofinnova, Neurotransmission, Clinical and Translational Gastroenterology, Methotrexate, De novo, EMA, Cancer, CTG, EULAR, Mall of America, FDA, Natural killer T cell, Safety, European Medicines Agency, Volunteering, Inflammatory Bowel Diseases, PIP, UEG, Ulcerative colitis, Publication, Blood, MTX, Nivolumab, Partnership, RA, ACR20, IBD, Bank statement, ECCO, Bristol Myers Squibb, CCO, Fungal infection, ASCO, EUR, Scripps, Food, Pharmaceutical industry, Management, Abivax, Rheumatology, UC, Gastroenterology

The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.

Key Points: 
  • The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.
  • Abivax recently reported the results of its Phase 2b maintenance trial of obefazimod in UC after two years of continued once-daily treatment with 50mg obefazimod.
  • In March 2022, Abivax announced its Phase 2a maintenance trial results of obefazimod in RA.
  • In January 2022, Abivax presented the results of the dose escalation phase of its Phase 1/2 clinical trial in HCC at the ASCO GI Cancers Symposium.

EBMI INKED MOA WITH SFIO TO BUILD A WORLD-CLASSS INTEGRATIVE CARE FACILITY IN PALAWAN, PHILIPPINES

Retrieved on: 
Monday, April 17, 2023
EW Group, Pictou County Wellness Centre, Partnership, Therapy, Research, Multimedia, Alternative medicine, European Technology Platform on Smart Systems Integration, Cosmeceutical, European Group, Mazumdar Shaw Medical Centre, Hospital, Ecosystem, Mall of America, SFIO, Starfleet, Airline, Pharmaceutical industry

The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.

Key Points: 
  • The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.
  • Through this partnership, both parties will develop and operate MORAYA's Integrative and Holistic Medicine facility, an eight-hectare eco-luxury community project, soon in Puerto Princesa, Palawan.
  • This project will provide a luxuriant and healthy-environment to the community mindfully designed to take holistic care of its residents.
  • The facility will be operated by using the EW Biological Regenerative systems and protocols, as well as treatment solutions and products developed by EW Group.

EBMI INKED MOA WITH SFIO TO BUILD A WORLD-CLASSS INTEGRATIVE CARE FACILITY IN PALAWAN, PHILIPPINES

Retrieved on: 
Monday, April 17, 2023
EW Group, Pictou County Wellness Centre, Partnership, Therapy, Research, Alternative medicine, European Technology Platform on Smart Systems Integration, Cosmeceutical, European Group, Mazumdar Shaw Medical Centre, Hospital, Ecosystem, Mall of America, SFIO, Starfleet, Airline, Pharmaceutical industry

MANILA, Philippines, April 17, 2023 /PRNewswire/ -- European Biological Medicine Inc., a subsidiary of European Wellness Biomedical Group (EW Group) has inked a Memorandum of Agreement (MoA) with Starfleet Innotech, Inc. (SFIO) to build a world-class integrative care facility in Palawan, Philippines under the MORAYA project, a real estate development company building wellness-oriented communities.

Key Points: 
  • MANILA, Philippines, April 17, 2023 /PRNewswire/ -- European Biological Medicine Inc., a subsidiary of European Wellness Biomedical Group (EW Group) has inked a Memorandum of Agreement (MoA) with Starfleet Innotech, Inc. (SFIO) to build a world-class integrative care facility in Palawan, Philippines under the MORAYA project, a real estate development company building wellness-oriented communities.
  • The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.
  • Through this partnership, both parties will develop and operate MORAYA's Integrative and Holistic Medicine facility, an eight-hectare eco-luxury community project, soon in Puerto Princesa, Palawan.
  • This project will provide a luxuriant and healthy-environment to the community mindfully designed to take holistic care of its residents.

Coloring the World with Kindness on National Crayon Day!

Retrieved on: 
Friday, March 31, 2023
Heart, Kindness, Business development, 1st Battalion, 120th Field Artillery Regiment, Mall of America, Multimedia, Creativity, Crayon, Collection, Mall, Imagination, Nightclub, Paraffin wax, Crayola

EASTON, Pa., March 31, 2023 /PRNewswire/ -- Thousands of kids and kids at heart are celebrating National Crayon Day today by helping Crayola Experience launch its Million Crayon Giveaway, which runs through May.

Key Points: 
  • EASTON, Pa., March 31, 2023 /PRNewswire/ -- Thousands of kids and kids at heart are celebrating National Crayon Day today by helping Crayola Experience launch its Million Crayon Giveaway, which runs through May.
  • Crayola Experience hopes to inspire kids to color the world with kindness with this year's Million Crayon Giveaway.
  • To help spread messages of kindness and positivity, Crayola Experience has added five crayons from the brand's Color of Kindness collection to the more than 70 different crayon colors that kids can choose from, making their custom box even more unique.
  • "Celebrating National Crayon Day and the Crayola crayon's 120th birthday is the perfect time to colorfully inspire happy thoughts, encourage positive interactions, and motivate acts of kindness and compassion," Schorr said.

Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

Retrieved on: 
Tuesday, March 21, 2023
PROTAC, Male, Hair, Androgen, University, Ars, New York University Grossman School of Medicine, Topical medication, Clinical trial, Pediatric Dermatology, DHT, Emerging, New York University, Research, Gene expression, Inflammation, Chimera, FAAD, Female, TAHC, Gland, HKEX, AGA, Miniaturization, AAD, BID, Growth, Pattern hair loss, Mall of America, Role, Phase, AR, University of Texas System, Birth control, Pharmaceutical industry, Vaccine, Dermatology, Acne, Dihydrotestosterone, Medicine

SUZHOU, China, March 21, 2023 /PRNewswire/ -- The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States.

Key Points: 
  • SUZHOU, China, March 21, 2023 /PRNewswire/ -- The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States.
  • Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939)'s self-developed and potential first-in-class topical drug candidates pyrilutamide (KX-826) and GT20029 have attracted a lot of attention at the meeting, demonstrating the company's innovative capabilities and the therapeutic potential of its androgenetic alopecia (AGA) and acne pipelines.
  • Dr. Adelaide Hebert said that androgens and androgen receptors would play a key role in acne pathogenesis and represent important treatment targets.
  • GT20029's Phase I clinical trials for treatment of AGA and acne in China and the US have been completed.

Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

Retrieved on: 
Wednesday, March 8, 2023
Pharmacist, Immune system, Brigham, Research, IND, BWH, Expanded access, Neurology, MS, Multiple sclerosis, National academy, Patient, EA, PNAS, Mall of America, Human, FDA, Vaccine, Pharmaceutical industry, COVID

The identification of a unique mechanism associated with nasal foralumab in humans was consistent across patients with COVID, multiple sclerosis and in healthy volunteers.

Key Points: 
  • The identification of a unique mechanism associated with nasal foralumab in humans was consistent across patients with COVID, multiple sclerosis and in healthy volunteers.
  • Furthermore, the unique immunomodulatory signature of intranasal foralumab makes it a promising therapeutic candidate for several rare Orphan pediatric neuroinflammatory diseases, which currently remain untreated.
  • The Company also notes Dr. Chitnis’s exciting desire to study intranasal foralumab in rare Orphan pediatric diseases.
  • Tiziana may pursue this unique and attractive opportunity when funding becomes available.”

Mars Honors 20 Change-Making Women Through M&M'S® Flipping the Status Quo Program In Celebration Of International Women's Day

Retrieved on: 
Wednesday, March 8, 2023
Friends, Mall of America, M&M, Poverty, Needle, Disability, Woman, Education, Mall, Music, Status Quo, Partnership, Gender, Times Square, Happiness, International Women's Day, Gretchen, International Women's Media Foundation, Organization, Sport, Female, Geena Davis Institute on Gender in Media, Family, Pharmaceutical industry, Interior design, Nursing, Toy, Tourism, Jewellery, Mars

NEWARK, N.J., March 8, 2023 /PRNewswire/ -- Today, M&M'S®, proudly part of Mars, announced the 20 winners of its "Flipping the Status Quo" program. These women were nominated by friends, family and colleagues for positively impacting the community around them and paving new paths for those who follow, redefining what happiness and success look like for women everywhere. M&M'S is thrilled to award each of these game-changing women with a $10,000 grant to further fund their missions.

Key Points: 
  • NEWARK, N.J., March 8, 2023 /PRNewswire/ -- Today, M&M'S®, proudly part of Mars, announced the 20 winners of its "Flipping the Status Quo" program.
  • The 20 women who are flipping the status quo include:
    Ahna Miller: Flipping the Status Quo in disability inclusion.
  • Earlier this year, M&M'S released its first-ever packs spotlighting the dynamic female M&M'S characters, in celebrations of women everywhere who are flipping the status quo.
  • As part of the Flipping the Status Quo campaign, M&M'S is providing nearly $1 million in support for organizations that are committed to uplifting and empowering women.

EQS-News: Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action

Retrieved on: 
Sunday, January 22, 2023
IBD, CET, Clinical and Translational Gastroenterology, Mall of America, IL-6, Euronext Paris, Inflammation, Inflammatory bowel disease, Publication, Patient, Cytokine, CTG, Maintenance, Therapy, MicroRNA, Immune system, Downregulation and upregulation, Ulcerative colitis, IL-17, Pharmaceutical industry, Abivax, UC

It reverses the expression of several inflammatory cytokines without impairing host defense as it does not impact the immune response altogether.

Key Points: 
  • It reverses the expression of several inflammatory cytokines without impairing host defense as it does not impact the immune response altogether.
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: “Abivax feels very encouraged by the data published in our article and the validation and extension of obefazimod’s novel and potent anti-inflammatory mechanism of action.
  • This specific MoA acts through the upregulation of a specific anti-inflammatory microRNA which reduces the expression of several pro-inflammatory cytokines.
  • We believe that obefazimod has the potential to also become an effective long-term therapy for other chronic inflammatory diseases with high medical need.”

Protein Tyrosine Phosphatase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Health, Pharmaceutical, Molecule, Product description, History, Administration, Route of administration, Mall of America, R, News, Research and development, Therapy, Research, EC, Key, Fine chemical, Medical device

The "Protein Tyrosine Phosphatase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Tyrosine Phosphatase Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Protein Tyrosine Phosphatase (EC 3.1.3.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Protein Tyrosine Phosphatase (EC 3.1.3.48) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Protein Tyrosine Phosphatase (EC 3.1.3.48) targeted therapeutics development and features dormant and discontinued projects.